MP29: Prostate Cancer: Advanced (including Drug Therapy) II

Poster Session Moderator(s)

• 

  Stephen Freedland, MD (he/him/his)

  Cedars-Sinai Medical Center
• 

  Robert Karnes, MD

  mayo clinic
• 

  Judd Moul, MD (he/him/his)

  James H Semans MD Professor of Surgery
  Duke University

Presentations:

• 7:00 AM – 9:00 AM CST

  MP29-01: Rapid, Durable, and Deep Prostate-Specific Antigen Response Following Addition of Darolutamide to Androgen-Deprivation Therapy and Docetaxel in ARASENS
  

  Poster Presenter: Fred Saad, MD (he/him/his) – University of Montreal Hospital Center
• 7:00 AM – 9:00 AM CST

  MP29-02: Efficacy and Safety of Darolutamide in Combination with Androgen-deprivation Therapy and Docetaxel in the North American Population from ARASENS
  

  Poster Presenter: Neal D. Shore, MD (he/him/his) – START Carolinas/Carolina Urologic Research Center
• 7:00 AM – 9:00 AM CST

  MP29-03: Multi-Institutional Analysis of Metastasis Directed Therapy With or Without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer
  

  Poster Presenter: Matthew Deek
• 7:00 AM – 9:00 AM CST

  MP29-04: Racial Differences in Percent of Men with Advanced Prostate Cancer Prescribed Targeted Agents Following Initiation of In-Office Pharmacies by Single Specialty Urology Practices
  

  Poster Presenter: Dawson Hill, BS (he/him/his)
• 7:00 AM – 9:00 AM CST

  MP29-05: Treatment Pattern and Health-Related Quality of Life (HRQoL) of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the United States (US)
  

  Poster Presenter: Neal D. Shore, MD (he/him/his) – START Carolinas/Carolina Urologic Research Center
• 7:00 AM – 9:00 AM CST

  MP29-06: Low pre-ADT testosterone level is related to earlier castration resistance in metastatic prostate cancer: a multicentre cohort study
  

  Poster Presenter: Ho Ming Chris Wong
• 7:00 AM – 9:00 AM CST

  MP29-07: APC mutation contributes to neuroendocrine differentiation and poor overall survival in metastatic prostate cancer patients
  

  Poster Presenter: Yuto Baba, MD – Department of Urology, Keio University School of Medicine
• 7:00 AM – 9:00 AM CST

  MP29-08: Risk of Neurocognitive Disorders in Prostate Cancer on Androgen Deprivation Therapy: A Meta-Analysis
  

  Poster Presenter: David E. Hinojosa-Gonzalez, MD – Massachusetts General Hospital
• 7:00 AM – 9:00 AM CST

  MP29-09: Identification of Prostate Cancer Metastatic Disease for Different Risk Groups based on FastText Word Embedding and Supervised Learning
  

  Poster Presenter: Ruixin Yang
• 7:00 AM – 9:00 AM CST

  MP29-10: Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA) targeted radionuclide therapy (TRT)
  

  Poster Presenter: Judith Stanglkremser, MD,PhD (she/her/hers)
• 7:00 AM – 9:00 AM CST

  MP29-11: Incidence of Cardiovascular Events in Men with BCR Following a Radical Prostatectomy: ADT Versus No ADT
  

  Poster Presenter: Joshua Tran, MS (he/him/his) – UCI Medical Center
• 7:00 AM – 9:00 AM CST

  MP29-12: Characteristics and Outcomes of Patients with Advanced Prostate Cancer Treated with Relugolix: A Single Center Experience
  

  Poster Presenter: Parth Vipul Shah, MD (he/him/his) – University of Wisconsin Hospitals and Clinics
• 7:00 AM – 9:00 AM CST

  MP29-13: Real-world Study on Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients Using a Urology Network in the United States (DEAR Study)
  

  Poster Presenter: Neal D. Shore, MD (he/him/his) – START Carolinas/Carolina Urologic Research Center
• 7:00 AM – 9:00 AM CST

  MP29-14: Prostate-Specific Antigen Response and Time-to-Castration Resistance among Patients with Metastatic Castration Sensitive Prostate Cancer Initiated on Apalutamide, Enzalutamide, or Abiraterone Acetate
  

  Poster Presenter: Benjamin Hugh Lowentritt, MD (he/him/his) – Chesapeake Urology Associates. P.A
• 7:00 AM – 9:00 AM CST

  MP29-15: Remotely-monitored sleep measures in prostate cancer patients undergoing androgen deprivation therapy (ADT)
  

  Poster Presenter: Brandon Noorvash, BA
• 7:00 AM – 9:00 AM CST

  MP29-16: Patients with stage M1a hormone-sensitive prostate cancer sensitively detected by PSMA-PET/CT benefit more from early docetaxel chemotherapy
  

  Poster Presenter: Zhangdong Jiang (he/him/his) – First Affiliated Hospital of XJTU
• 7:00 AM – 9:00 AM CST

  MP29-17: Efficacy and feasibility of additional cycles of docetaxel in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
  

  Poster Presenter: Can Aydogdu, MD (he/him/his) – LMU University Hospital Munich
• 7:00 AM – 9:00 AM CST

  MP29-18: Oncological outcomes in the metastatic low tumor-burden prostate cancer are not significantly different from the locally advanced (T4 or N1) prostate cancer
  

  Poster Presenter: Toshikazu Tanaka (he/him/his)
• 7:00 AM – 9:00 AM CST

  MP29-19: Pre-operative plasma metabolites can predict the risk of bone metastasis in prostate cancer
  

  Poster Presenter: George Niklaus Thalmann, MD (he/him/his) – University of Berne
• 7:00 AM – 9:00 AM CST

  MP29-20: FACTORS ASSOCIATED WITH POOR SURVIVAL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS WITH RADIOGRAPHIC DISEASE PROGRESSION IN THE SETTING OF LOW PSA
  

  Poster Presenter: Mohamed El Sayed Hassan Ahmed, MD (he/him/his) – Mayo Clinic